Valuation: Alector, Inc.

Market Cap 229M 200M 184M 171M 325M 21.78B 330M 2.21B 858M 10.7B 858M 840M 36.89B P/E 2026 *
-2.4x
P/E 2027 * -3.21x
Enterprise Value -18.42M -16.1M -14.8M -13.8M -26.17M -1.75B -26.56M -178M -69.07M -862M -69.15M -67.66M -2.97B EV / Sales 2026 *
-2.69x
EV / Sales 2027 * -4.27x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+2.49%
1 week+10.75%
Current month+2.49%
1 month+16.06%
3 months-14.52%
6 months+34.64%
Current year+32.05%
1 week 1.77
Extreme 1.77
2.14
1 month 1.41
Extreme 1.41
2.14
Current year 1.41
Extreme 1.41
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
40.39
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 2013-04-30
Director of Finance/CFO 53 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 72 2024-03-18
Chairman 77 2023-06-12
Director/Board Member 72 2018-09-30
Date Insider Type Main position Quantity % Market Cap.
Jun. 16Free

Director

38,150 0.0344%
Jun. 16Free

Chairman

38,150 0.0344%
Jun. 16Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
+2.49%+10.75%+36.42%-65.84% 229M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.83%+8.84%+52.81%+124.27% 24.57B
Weighted average by Cap. +2.46%+6.48%+59.04%+137.51%

Financials

2026 *2027 *
Net sales 6.86M 5.99M 5.51M 5.13M 9.74M 653M 9.89M 66.13M 25.71M 321M 25.74M 25.19M 1.11B 22.88M 20M 18.38M 17.13M 32.5M 2.18B 32.99M 221M 85.79M 1.07B 85.89M 84.04M 3.69B
Net income -94.11M -82.27M -75.61M -70.47M -134M -8.96B -136M -908M -353M -4.4B -353M -346M -15.18B -96.62M -84.46M -77.62M -72.35M -137M -9.2B -139M -932M -362M -4.52B -363M -355M -15.58B
Net Debt -247M -216M -199M -185M -351M -23.53B -356M -2.38B -927M -11.57B -928M -908M -39.86B -326M -285M -262M -244M -464M -31.07B -471M -3.15B -1.22B -15.27B -1.23B -1.2B -52.64B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-07-02 $2.060 +2.49% 394,059
26-07-01 $2.010 0.00% 368,534
26-06-30 $2.010 -3.37% 609,377
26-06-29 $2.080 +11.83% 544,170
26-06-26 $1.860 +0.54% 3,845,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.060USD
Average target price
3.100USD
Spread / Average Target
+50.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock